Form 4: Alnylam CCO's Stock Transactions Post-PSU Vesting

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, acquired shares from a performance-based unit vesting and subsequently sold shares to cover tax obligations.

Summary

• Tolga Tanguler, EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, acquired 3,800 shares of common stock on January 11, 2026.
• This acquisition resulted from the vesting of 40% of a performance-based stock unit (PSU) granted on March 1, 2024.
• The vesting was triggered by Alnylam publicly reporting $2.5 billion in annual net product revenue, as determined by the People, Culture and Compensation Committee.
• On January 12, 2026, Tanguler sold a total of 1,164 shares of common stock in multiple transactions.
• These sales were mandatory "sell-to-cover" transactions to satisfy minimum statutory tax withholding obligations related to the PSU vesting.
• The shares were sold at weighted average prices ranging from $353.95 to $377.82.
• Following these transactions, Tanguler's direct beneficial ownership of common stock decreased from 31,238 shares to 29,728 shares.

Sentiment

Score: 7

Explanation: The filing indicates strong company performance through the achievement of a significant revenue target, leading to the vesting of executive performance-based stock units. While there are sales, they are routine 'sell-to-cover' for tax purposes, not discretionary sales, which is a neutral to slightly positive signal.

Positives

• Vesting of performance-based stock units indicates the achievement of a significant company performance metric: $2.5 billion in annual net product revenue.
• The acquisition of 3,800 shares at a $0.0 price reflects a gain for the reporting person.

Negatives

• The sale of 1,164 shares, even for tax purposes, reduces the reporting person's direct ownership in the company.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report. The achievement of a $2.5 billion annual net product revenue target by Alnylam Pharmaceuticals suggests strong commercial performance, which is a positive indicator within the competitive biotechnology and pharmaceutical industry.

Comparison to Industry Standards

• The achievement of a $2.5 billion annual net product revenue target is a significant milestone for a biotechnology company, indicating successful commercialization of its products. This level of revenue places Alnylam among established mid-to-large cap pharmaceutical companies, distinguishing it from many smaller biotech firms still in clinical development stages.
• The "sell-to-cover" mechanism for tax obligations on vested equity awards is a standard practice across industries, particularly in high-growth sectors like biotechnology where equity compensation is prevalent. This is comparable to practices at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals, where executives often sell a portion of vested shares to manage tax liabilities.

Stakeholder Impact

• Shareholders: The achievement of the $2.5 billion revenue target is a positive signal for shareholders, indicating strong operational performance and potential for future growth. The executive's continued ownership, even after tax-related sales, aligns interests with shareholders.
• Employees: Successful achievement of company goals and executive compensation vesting can positively impact employee morale and confidence in the company's direction.

Key Dates

Recommendation

The filing reveals a positive operational milestone with the achievement of a $2.5 billion revenue target, leading to executive PSU vesting. This indicates strong underlying business performance. The subsequent share sales are non-discretionary, solely for tax obligations, and do not signal a lack of confidence from the executive. Given the positive operational news, but the routine nature of the insider sales, a 'hold' recommendation is appropriate for investors to observe further financial reporting and strategic developments. The stock price has already reacted to the underlying performance that triggered the vesting.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, Insider Trading, Stock Transaction, Performance Stock Unit, PSU, Executive Compensation, Tax Withholding, Tolga Tanguler, Biotechnology, Pharmaceuticals